Sanofi and Regeneron report positive top-line results with alirocumab from first Phase 3 study of a PCSK9 inhibitor for LDL cholesterol reduction

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint. The mean low-density lipoprotein-cholesterol (LDL-C, or "bad" cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab, as compared to patients randomized to ezetimibe (47.2% vs. 15...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/fLp87sPl6NU/267572.php

sport medical sport news